65,437 trials
Knee Instability
Primary: Static Knee Stability
Migraine Disorders
Primary: Number of Participants With the Indicated Drug-related Adverse Events — 93; 46; 170; 19 participants
Prostate Cancer
Primary: Overall Survival — 21.7; 25.8 Months — p=0.032
Type 2 Diabetes
Primary: Hemoglobin A1c (HbA1c) Change From Baseline to Week 52 — 7.46; 7.53; 6.74; 6.71 Percent
Palmoplantar Psoriasis
Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants
Hormone-Refractory Prostate Cancer
Primary: Overall Time to Disease Progression — 10.9; 9.9 Weeks — p=0.719
Corneal Epithelial Defect · Diabetic Retinopathy · Penetrating Keratoplasty
Primary: Patients With Corneal Epithelial Healing Time Within 14 Days — 78; 73 participants
Gaucher Disease
Primary: Participants Who Experienced at Least One Adverse Event — 34 participants
Kidney Disease · Diabetes Mellitus · Anemia
Primary: Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial…
Type 2 Diabetes Mellitus
Primary: Change in Glycosylated Hemoglobin (HbA1c) — -0.84; -0.10 Percentage — p=<0.001
Obstructive Sleep Apnea
Primary: Compliance on CPAP — 6.58; 7.07; 6.72 Hours
Hypertension
Primary: Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP). — -17.8; -16.5; -14.8; -21.5 mm Hg — p=<0.0001
Fibroid · Myoma · Leiomyoma
Primary: Number of Sites Adherent to the Uterus — 1.1; 0.6 Adhesion Sites
Alcoholism
Primary: Number of Days on Which Subjects Drank — 37.0; 33.8 days
Asthma · Bronchial Hyperresponsiveness
Primary: Adenosine Challenge Test — 18.46; 142.61 mg/ml